We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will New Technologies Benefit Agilent (A) in Q2 Earnings?
Read MoreHide Full Article
Agilent Technologies (A - Free Report) is set to report fiscal second-quarter 2018 results on May 14. In the last reported quarter, it delivered a positive earnings surprise of 13.79%.
The company’s surprise history has been pretty impressive. It beat estimates in each of the trailing four quarters, with an average positive earnings surprise of 13.61%.
Notably, on a 12-month basis, Agilent’s shares have returned 22.5%, underperforming the industry’s gain of 17.6%.
Let’s see how things are shaping up for this announcement.
Strength in ACG Segment to Drive Revenues
In the last reported quarter, the Agilent Cross Lab Group (ACG) revenues came in at $408 million. Both services and consumables witnessed growth. China and Food led growth across all regions and major end-markets.
The figure is expected to further increase in the to-be-reported quarter, driven by strength in services and consumables across all geographical regions. The Zacks Consensus Estimate for the quarter to be reported is pegged at $419 million.
Strength in DGG & LSAG Serve As Big Positives
In the last reported quarter, revenues from the company’s Diagnostics and Genomics Group (DGG) came in at $185 million, up year over year driven by strength in pharma, diagnostic and clinical end-markets. All businesses under this group (Dako, Genomics and Nucleic Acid Solutions) performed well. The segment is also expected to perform well in the soon-to-be-reported quarter. The Zacks Consensus Estimate for the fiscal second quarteris pegged at $223 million.
Also, the Life Sciences & Applied Markets Group (LSAG) segment is expected to perform well in the quarter, driven by strong performances in chemical and energy, and pharma and environmental markets. The Zacks Consensus Estimate for the fiscal second quarter is pegged at $555 million.
Other Growth Drivers
Agilent Technologies is a broad-based OEM of test and measurement equipment. The company has shifted its focus to life sciences, genomics, diagnostics and wireless test markets, in which it has made a few important acquisitions and alliances.
Agilent’s broad-based portfolio and increased focus on its segments offer higher growth potential. The company’s decision to divest/wind up underperforming businesses has enhanced its focus on the new Agilent, while enabling expansion of a solid recurring revenue base, and diversification of geographic and industrial operations for growth. Also, the company’s focus on aligning investments toward more attractive growth avenues and innovative product launches is also a positive.
However, macro weakness in some regions and unfavorable foreign exchange remain concerns.
What Our Model Suggests
According to the Zacks model, a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has a good chance of beating estimates if it also has a positive Earnings ESP.
Zacks Rank #4 (Sell) or 5 (Strong Sell) stocks are best avoided, especially if these have a negative Earnings ESP. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Agilent Technologies has a Zacks Rank #2 and an Earnings ESP of -2.48%, a combination that does not suggest that the company is likely to beat estimates this time around.
Rexnord Corporation has an Earnings ESP of +1.82% and a Zacks Rank of 2.
GAIN Capital Holdings, Inc. (GAIN - Free Report) has an Earnings ESP of +5.56% and a Zacks Rank #3.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Will New Technologies Benefit Agilent (A) in Q2 Earnings?
Agilent Technologies (A - Free Report) is set to report fiscal second-quarter 2018 results on May 14. In the last reported quarter, it delivered a positive earnings surprise of 13.79%.
The company’s surprise history has been pretty impressive. It beat estimates in each of the trailing four quarters, with an average positive earnings surprise of 13.61%.
Notably, on a 12-month basis, Agilent’s shares have returned 22.5%, underperforming the industry’s gain of 17.6%.
Let’s see how things are shaping up for this announcement.
Strength in ACG Segment to Drive Revenues
In the last reported quarter, the Agilent Cross Lab Group (ACG) revenues came in at $408 million. Both services and consumables witnessed growth. China and Food led growth across all regions and major end-markets.
The figure is expected to further increase in the to-be-reported quarter, driven by strength in services and consumables across all geographical regions. The Zacks Consensus Estimate for the quarter to be reported is pegged at $419 million.
Strength in DGG & LSAG Serve As Big Positives
In the last reported quarter, revenues from the company’s Diagnostics and Genomics Group (DGG) came in at $185 million, up year over year driven by strength in pharma, diagnostic and clinical end-markets. All businesses under this group (Dako, Genomics and Nucleic Acid Solutions) performed well. The segment is also expected to perform well in the soon-to-be-reported quarter. The Zacks Consensus Estimate for the fiscal second quarteris pegged at $223 million.
Also, the Life Sciences & Applied Markets Group (LSAG) segment is expected to perform well in the quarter, driven by strong performances in chemical and energy, and pharma and environmental markets. The Zacks Consensus Estimate for the fiscal second quarter is pegged at $555 million.
Other Growth Drivers
Agilent Technologies is a broad-based OEM of test and measurement equipment. The company has shifted its focus to life sciences, genomics, diagnostics and wireless test markets, in which it has made a few important acquisitions and alliances.
Agilent’s broad-based portfolio and increased focus on its segments offer higher growth potential. The company’s decision to divest/wind up underperforming businesses has enhanced its focus on the new Agilent, while enabling expansion of a solid recurring revenue base, and diversification of geographic and industrial operations for growth. Also, the company’s focus on aligning investments toward more attractive growth avenues and innovative product launches is also a positive.
However, macro weakness in some regions and unfavorable foreign exchange remain concerns.
What Our Model Suggests
According to the Zacks model, a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has a good chance of beating estimates if it also has a positive Earnings ESP.
Zacks Rank #4 (Sell) or 5 (Strong Sell) stocks are best avoided, especially if these have a negative Earnings ESP. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Agilent Technologies has a Zacks Rank #2 and an Earnings ESP of -2.48%, a combination that does not suggest that the company is likely to beat estimates this time around.
Agilent Technologies, Inc. Price and EPS Surprise
Agilent Technologies, Inc. Price and EPS Surprise | Agilent Technologies, Inc. Quote
Stocks to Consider
We see likely earnings beat for each of the following companies:
Thomson Reuters Corporation (TRI - Free Report) has an Earnings ESP of +7.36% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Rexnord Corporation has an Earnings ESP of +1.82% and a Zacks Rank of 2.
GAIN Capital Holdings, Inc. (GAIN - Free Report) has an Earnings ESP of +5.56% and a Zacks Rank #3.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>